Purple Biotech (PPBT) Non-Current Assets (2015 - 2026)

Purple Biotech (PPBT) has 12 years of Non-Current Assets data on file, last reported at $7.6 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $7.6 million, down 72.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.6 million (down 72.8% YoY), and the FY2025 annual result was $7.7 million, down 72.61% from the prior year.
• Non-Current Assets declined to $7.6 million in Q1 2026 per PPBT's latest filing, from $7.7 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $28.7 million in Q1 2023 and troughed at $7.6 million in Q1 2026.
• A 5-year average of $24.8 million and a median of $28.1 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2026: Non-Current Assets surged 33.46% in 2023, then plunged 72.8% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $21.4 million in 2022, then surged by 33.46% to $28.5 million in 2023, then dropped by 1.35% to $28.1 million in 2024, then plunged by 72.61% to $7.7 million in 2025, then slipped by 0.88% to $7.6 million in 2026.
• Business Quant data shows PPBT's Non-Current Assets at $7.6 million in Q1 2026, $7.7 million in Q4 2025, and $28.3 million in Q3 2025.